VG161
AXP000082.1 · Oncolytic virus
- Platform
- HSV-1 (ICP34.5- ICP47-)
- Originator
- Virogin Biotech
- Sponsor
- CNBG-Virogin Biotech (Shanghai)
Names
| Name | Type | Source |
|---|---|---|
| VG161 | preferred name, code | curator, ncit |
| Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell) | synonym | ctgov |
Virus
- Role
- Oncolytic
- Family
- Orthoherpesviridae
- Virus
- herpes simplex virus 1 (NCBI Taxonomy 10298)
- Replication
- conditionally replicating
- Modifications
- ICP34.5 and ICP47 deleted
- Transgenes
- IL12A, IL12B, IL15, IL15RA, PD-L1 blocking peptide
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C179675
Approvals
No regulatory approval recorded.
Clinical trials (9)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05223816 | An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma | Unknown | Phase 2 | 2024-01-24 | 2025-10-01 | 97 | Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma |
| NCT06124001 | Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma | Unknown | Phase 1/2 | 2023-11-30 | 2025-12-30 | 36 | Primary Hepatocellular Carcinoma |
| NCT06126510 | Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma | Recruiting | Phase 2 | 2023-07-18 | 2025-07-17 | 40 | Sarcoma |
| NCT06008925 | Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer | Unknown | Phase 1/2 | 2022-11-17 | 2025-12 | 43 | Metastatic Gastric Cancer |
| NCT06746480 | Clinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma | Recruiting | Phase 2 | 2022-03-19 | 2025-09-30 | 33 | Advanced Intrahepatic Cholangiocarcinoma |
| NCT05162118 | Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer | Unknown | Phase 1/2 | 2022-03-08 | 2025-03-22 | 51 | Advanced Pancreatic Cancer |
| NCT07505615 | A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer | Completed | Phase 1/2 | 2021-10-12 | 2023-04-28 | 20 | NMIBC |
| NCT04758897 | Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors | Unknown | Phase 1 | 2021-04-14 | 2022-03-14 | 18 | Advanced Malignant Solid Tumor |
| NCT04806464 | Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer | Unknown | Phase 1 | 2021-03-16 | 2022-03-21 | 44 | Primary Liver Cancer |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40108464 | Oncolytic virus VG161 in refractory hepatocellular carcinoma. | Nature | 2025 | cited by trial NCT04806464 |
| PMID 38638849 | Oncolytic virotherapy stimulates anti‑tumor immune response and demonstrates activity in advanced sarcoma: Report of two cases. | Oncology letters | 2024 | name in abstract: VG161 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42362102 | VG161 oncolytic virus remodels the tumor microenvironment by expanding CD3+ macrophages and enhancing antitumor immunity. | Cancer letters | 2026 | name in title: VG161 |
| PMID 42371785 | Radiotherapy Enhances the Oncolytic Efficacy of the Novel Oncolytic Herpesvirus VG161 and Amplifies Its Antitumor Immunity in Breast Cancer. | Advanced science (Weinheim, Baden-Wurttemberg, Germany) | 2026 | name in title: VG161 |
| PMID 42909267 | Liver-resident cellular determinants of oncolytic virotherapy in hepatocellular carcinoma: viral susceptibility and spatial immune remodeling. | Frontiers in cell and developmental biology | 2026 | name in abstract: VG161 |
| PMID 40269171 | Publisher Correction: Oncolytic virus VG161 in refractory hepatocellular carcinoma. | Nature | 2025 | name in title: VG161 |
| PMID 40718827 | Oncolytic virus VG161 offers new hope for refractory liver cancer. | Frontiers in oncology | 2025 | name in title: VG161 |
| PMID 41022576 | Hypothesis-generating evaluation of multi-armoured oncolytic HSV-1 (VG161) in intrahepatic cholangiocarcinoma: pooled insights from multicentre studies. | Gut | 2025 | name in title: VG161 |
| PMID 41231105 | Immune reprogramming of cold tumors using TGF-β/PD-L1 bispecific antibody and armed oncolytic virus therapy. | Advances in clinical and experimental medicine : official organ Wroclaw Medical University | 2025 | name in abstract: VG161 |
| PMID 36042555 | VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes. | Journal of medical virology | 2023 | name in title: VG161 |
| PMID 37212336 | Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy. | Journal of medical virology | 2023 | name in abstract: VG161 |
| PMID 36366425 | Pre-Existing HSV-1 Immunity Enhances Anticancer Efficacy of a Novel Immune-Stimulating Oncolytic Virus. | Viruses | 2022 | name in abstract: VG161 |
| PMID 33182232 | Induction of Durable Antitumor Response by a Novel Oncolytic Herpesvirus Expressing Multiple Immunomodulatory Transgenes. | Biomedicines | 2020 | name in abstract: VG161 |
Notes
Registered in China as 'recombinant human IL12/IL15-PDL1B oncolytic HSV-1 injection (Vero cell)'. Trials in hepatocellular carcinoma, cholangiocarcinoma, pancreatic and gastric cancer.
How to cite
VG161 (AXP000082.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000082.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.